On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.

On the news front, Da Hua Securities initiated coverage on the company with a \"Buy\" rating and a target price of 29 HKD, noting the company possesses the most comprehensive surgical robot product portfolio in the industry, spanning laparoscopic, orthopedic, vascular, and urological applications. Its flagship Toumai and Honghu systems have received market approval in China and the EU.

Concurrently, the company previously issued a positive profit alert, projecting H1 net profit of RMB 28-40 million versus a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue surged approximately 200%-230% year-over-year, with Toumai robot overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points. Haitong International attributed the turnaround to revenue growth, margin expansion, and enhanced expense management working in concert.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)